Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results
May 07 2020 - 4:05PM
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage
biotechnology company targeting cancers caused by dysregulated gene
expression, today announced that the Company will host a conference
call and live audio webcast on Thursday, May 14, 2020, at 4:30
p.m. ET, to discuss its corporate and financial results for the
first quarter 2020.
Conference Call Information: Interested
participants and investors may access the conference call by
dialing either:
- (833) 423-0481 (U.S.)
- (918) 922-2375 (international)
- Conference ID: 6281273
An audio webcast will be accessible via the
Investors Events and Presentations section of the Company’s
website http://investors.salariuspharma.com/. An archive of
the webcast will remain available for 90 days beginning at
approximately 5:30 p.m. ET, on May 14, 2020.
About Salarius Pharmaceuticals,
Inc.Salarius Pharmaceuticals, Inc. is a
clinical-stage oncology company targeting the epigenetic causes of
cancers and is developing treatments for patients that need them
the most. Epigenetics refers to the regulatory system that affects
gene expression. Salarius’ lead candidate, Seclidemstat, is
currently in clinical development (Phase 1/2 trial) for treating
relapsed/refractory Ewing sarcoma, a rare and devastating pediatric
and young adult bone and soft tissue cancer, for which it has
received Fast Track Designation, Orphan Drug Designation and Rare
Pediatric Disease Designation from the U.S. Food and Drug
Administration. Salarius is also developing Seclidemstat for a
number of other cancers, with a second Phase 1/2 clinical study
targeting advanced solid tumors, including prostate, breast and
ovarian cancers.
Investor/Media Relations Tiberend Strategic
Advisors, Inc.Maureen McEnroe/ Johanna Bennett(212)
375-2664/2686mmcenroe@tiberend.com/jbennett@tiberend.com
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Jul 2023 to Jul 2024